AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06348407
Drug: IgE monoclonal antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: omalizumab
Trial: NCT05963048
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion 1000 mg
Trial: NCT05963048
Drug: IL6 inhibitor
RxNorm normalized name: IL6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg I V infusion monthly
Trial: NCT05847348
Drug: 68Ga-PSMA-11
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
Trial: NCT06067269
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05154279
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramyometrial terlipressin vs carbitocin vs saline as placebo
Trial: NCT06473896
Drug: Ketalar
RxNorm normalized name: Ketalar
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a dissociative anesthetic used medically for induction and maintenance of anesthesia
Trial: NCT06473896
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an agonist of α2-adrenergic receptors in certain parts of the brain used for sedation
Trial: NCT06757894
Drug: Zuberitamab
RxNorm normalized name: ZUBERITAMAB
DrugBank: ZUBERITAMAB (DB19443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)
Trial: NCT06757894
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90 mg/m², administered on D1-2 of C1-C6
Trial: NCT06553352
Drug: Zanubrutinib combined with Obinutuzumab
RxNorm normalized name: Zanubrutinib
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib combined with Obinutuzumab (ZO), a specific dose on specific days.
Trial: NCT04852523
Drug: 18F-fluciclovine
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 18F-Fluciclovine is a synthetic L-leucine amino acid used clinically for PET imaging in patients with biochemical recurrence of prostate cancer following definitive therapy. The pancreas accumulates striking amounts of Axumin, where it is considered a normal finding. Pancreatic beta-cell function may be slow to recover following pancreatic transplantation and may vary as a function of perioperative steroid administration, acute rejection, inadequate islet cell transplantation, allograft pancreatitis or compromised blood supply. Viability of the allograft is a common clinical concern and is difficult to assess based on insulin, C-peptide, and blood sugar levels. Rapid identification of compromised allograft viability is critical in the management of these patients.
Trial: NCT06748664
Drug: Rimegepant ODT 75mg , EOD treatment for 4/12* weeks
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All Participants will receive either Rimegepant 75 mg every other day for 4 weeks, followed by a 4-week observational phase.
Trial: NCT06748105
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 10mg/day of dapagliflozin orally. The administration will occur within a synchronous range, meaning that the time difference between dapagliflozin administration and glucocorticoid administration should not exceed 12 hours.
Trial: NCT06752785
Drug: CAR-T Therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19/CD22 CAR-T cell therapy
Trial: NCT06755515
Drug: Rulonilimab
RxNorm normalized name: Rulonilimab
DrugBank: Rulonilimab (DB18922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Rulonilimab Description: iv, 200mg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.
Trial: NCT06755515
Drug: cisplatin/carboplatin + paclitaxel ± bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cisplatin/carboplatin + paclitaxel ± bevacizumab
Trial: NCT03029481
Drug: Ganitumab
RxNorm normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
Trial: NCT06751524
Drug: Botensilimab
RxNorm normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).
Trial: NCT06751524
Drug: Balstililmab
RxNorm normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).
Trial: NCT05496894
Drug: Mitoxantrone Hydrochloride Liposome Injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV, once every 3 months (Q3M)
Trial: NCT06756126
Drug: AK120
RxNorm normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AK120 subcutaneous injection
Trial: NCT06751953
Drug: Neoantigen-loaded DC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Trial: NCT05668858
Drug: SI-B001
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT05668858
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion
Trial: NCT04908514
Drug: ADX-629
RxNorm normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX-629 administered orally twice daily (BID) for approximately 12 weeks.
Trial: NCT05977023
Drug: NMDAE
RxNorm normalized name: NMDA
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer for the treatment of bipolar depression
Trial: NCT06757387
Drug: chidamide and golidocitinib
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Golidocitinib (DB18057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive combination therapy with golidocitinib (150 mg QD or 150 mg QOD) and chidamide (20 mg BIW or 25 mg BIW)； If the MTD is determined at Dose Level 1 (chidamide 20 mg BIW / golidocitinib 150 mg QD), Dose Level 0 (chidamide 20 mg BIW / golidocitinib 150 mg QOD) will be further investigated. If the MTD is not established after escalating to Dose Level 2 (chidamide 25 mg BIW / golidocitinib 150 mg QD), the recommended Phase 2 dose (RP2D) will be determined through investigator consensus.
Trial: NCT06758557
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m² iv d1
Trial: NCT06758557
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175 mg/m² iv d1
Trial: NCT06758557
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 5 iv d1
Trial: NCT06757257
Drug: fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral administration
Trial: NCT06757504
Drug: TTYP01 Tablets (12mg or 18mg)
RxNorm normalized name: edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
Trial: NCT04762472
Drug: Montelukast Oral Tablet
RxNorm normalized name: montelukast Oral Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i) Montelukast 10mg daily (tablet) orally x 26 weeks
Trial: NCT04762472
Drug: Montelukast Placebo Oral Tablet
RxNorm normalized name: placebo Oral Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i) Placebo (Montelukast identical) tablet 1 daily orally x 26weeks
Trial: NCT06751589
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly.
Trial: NCT06760260
Drug: Human Derived anti-CI135 CAR-T Injection
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous genetically modified anti-CI135 CAR transduced T cells
Trial: NCT06760195
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
Trial: NCT06760065
Drug: Keverprazan Hydrochloride tablets + high dose amoxicillin
RxNorm normalized name: amoxicillin Chewable Tablet
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Keverprazan Hydrochloride, a potassium-competitive acid blocker (P-CAB), is administered at a dose of 20 mg twice daily in combination with Amoxicillin 0.75 g four times daily for 14 days. This dual therapy is designed to provide rapid and sustained gastric acid suppression and evaluate its efficacy in eradicating Helicobacter pylori.
Trial: NCT06759090
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab: a PD-1 inhibitor, 200 mg, intravenous injection once every 2 weeks;
Trial: NCT06759090
Drug: Apatinib Mesylate Tablets
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with water within 30 minutes after a meal.
Trial: NCT06760078
Drug: intravenous tranexamic acid (TXA) infusion
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid will be administered as an initial dose of 1 g (10mL: 1g, diluted in 90 mL normal saline) over 10 minutes, followed by a maintenance dose of 1 g over 8 hours (10mL: 1g, diluted in 240 mL normal saline). Intensive blood pressure lowering will be maintained throughout the treatment period until 24 hours after onset.
Trial: NCT04669561
Drug: Lifitegrast 5% Ophthalmic Solution
RxNorm normalized name: Lifitegrast 5% Ophthalmic Solution
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
Trial: NCT06301191
Drug: Semaglutide, 1.0 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide, 1.0 mg/mL
Trial: NCT06301191
Drug: Dipeptidyl Peptidase 4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipeptidyl Peptidase 4 inhibitor
Trial: NCT06582485
Drug: iCM012 solution 2 mg/mL
DrugBank: M012 (DB18243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
Trial: NCT06756152
Drug: Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The most significant adverse events limiting the use of HSCT from an unrelated donor are graft-versus-host disease (GVHD) and prolonged immunodeficiency associated with the development of severe infectious complications. The use of post-transplant cyclophosphamide for the prevention of GVHD during allogeneic HSCT from unrelated and haploidentical donors has reduced the incidence of acute clinically significant GVHD in children to 25%, chronic GVHD to 12-30%, but the issue of GVHD control still remains extremely relevant. Emerging data on the use of abatacept, a selective blocker of the costimulatory signal from an antigen-presenting cell, in the prevention of intestinal GVHD and data on the effectiveness of Janus-kinase type 1/2 inhibitors (JAK-1/2) in the treatment and prevention of acute GVHD allow us to justify the use of these drugs in combination with post-transplant cyclophosphamide as a promising pharmacological platform for the prevention of GVHD.
Trial: NCT06752057
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
Trial: NCT06752057
Drug: Neoantigen-loaded DC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Trial: NCT06716840
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: participants in the remimazolam group received remimazolam besylate intravenously at an initial infusion rate of 0.2mg/kg/h and adjusted (maximum of 2 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale(RASS) score between - 2 and 0.If the maximum dose of remimazolam was insufficient to sedate, add rescue dexmedetomidine.
Trial: NCT06716840
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants in the propofol group received propofol intravenously at an initial infusion rate of 1 mg/kg/h and adjusted (maximum of 4 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale (RASS) score between - 2 and 0.If the maximum dose of propofol was insufficient to sedate, add rescue dexmedetomidine.
Trial: NCT05550506
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who use duloxetine for chronic pain or fibromyalgia
Trial: NCT01990586
Drug: Rabeprazole sodium 20 mg Delayed Release tablet
RxNorm normalized name: rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05113784
Drug: Meplazumab for Injection
RxNorm normalized name: mepolizumab Injection
DrugBank: Meplazumab (DB16465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humanized antibody target CD147
Trial: NCT05113784
Drug: Sterile normal saline (0.9%)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9%)
Trial: NCT06647342
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
Trial: NCT06427850
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: receive an injection of Tranexamic acid into the surgical site
Trial: NCT04877457
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
Trial: NCT05134363
Drug: Dexmedetomidine Hydrochloride 0.5 mic/kg bolus
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparison between two bolus doses of dexmedetomidine with a placebo group
Trial: NCT05134363
Drug: Dexmedetomidine Hydrochloride 0.75 mic/kg bolus
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
Trial: NCT05054257
Drug: Autologous CAR19 T lymphocytes
RxNorm normalized name: Lapine T-lymphocyte immune globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
Trial: NCT04940624
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat mini-tablets or tablets.
Trial: NCT05975528
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the SGLT2 inhibitor group, total drug adminstration days are 180 days, but non-SGLT2 inhibitor administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.~For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered.
Trial: NCT05975528
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For non-SGLT2 inhibitor (glimepiride) administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.
Trial: NCT04867369
Drug: Bupivacaine 20mL 0.5%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interscalene nerve block with 20 mL 0.5% bupivacaine.
Trial: NCT04867369
Drug: Bupivacaine 20mL 0.25%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pecs II fascial plane block with 20 mL 0.25% bupivacaine.
Trial: NCT04867369
Drug: Bupivacaine up to 15mL 0.25%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.
Trial: NCT06253806
Drug: Stellate Ganglion Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 1% mepivacaine will be injected near the stellate ganglion.
Trial: NCT00002031
Drug: Dinitrochlorobenzene
RxNorm normalized name: Dinitrochlorobenzene
DrugBank: Dinitrochlorobenzene (DB11831)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06758726
Drug: Mitoxantrone Hydrochloride Liposome combined with BU/Cy
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day -9, iv Busulfan (3.2mg/kg/d) on day -7\~-5, iv Cyclophosphamide (60 mg/kg/d) on day -3\~-2, iv
Trial: NCT06759857
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib is an approved, second-generation, irreversible EGFR tyrosine kinase inhibitor used as a standard first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, such as L858R and Exon 19 deletions. Participants in this arm will take a 40 mg oral dose once daily. Afatinib serves as the active comparator in this study to evaluate the efficacy and safety of FHND9041.
Trial: NCT06759649
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06759584
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To Compare clinical outcome of dexamethasone phonophoresis in a (continuous and pulsed) maneuver for management of Temporomandibular Disorders
Trial: NCT06758596
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.